Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$1.29
EPS est.
$1.28
EPS surprise
+1.02%
1-day move
+3.23%
Haemonetics Corporation reported a better-than-expected EPS for Q4-2026, which likely contributed to the positive stock reaction, with shares rising by 3.23%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance. Investors may be encouraged by the EPS beat, but the lack of revenue data and guidance could lead to caution in the market.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.29 | $1.27 | +1.02% |
| Revenue | — | $337M | — |
No transcript is on record, and the analysis is based on numerical results only.
Haemonetics Corporation operates in the health care sector, focusing on medical supplies that help manage blood and blood components. As a key player in this industry, the company plays a vital role in improving patient outcomes and enhancing the efficiency of blood management systems.
Last quarter
In Q3-2026, Haemonetics reported an EPS of $1.31, exceeding expectations by 3.15%. However, there was no revenue estimate provided, and the stock reacted negatively, dropping 1.41% the following day.
Management promises and guidance
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
-0.43%
Avg 1-day reaction
+1.78%
Analysts are cautiously optimistic about Haemonetics' upcoming earnings, expecting it to meet or slightly exceed EPS and revenue estimates.
Bull case
If the company reports strong demand for its blood management products and maintains or improves profit margins, it could lead to a positive stock reaction.
Bear case
Conversely, if the company fails to meet EPS expectations or reports declining sales, it could trigger a significant drop in the stock price.
Key metrics to watch
EPS
$1.27Earnings per share is a critical measure of profitability and will indicate how well Haemonetics is managing its costs and generating revenue.
Revenue
$337MRevenue figures will provide insight into the company's sales performance and overall demand for its products in the health care market.
The print will turn on these.
Q1
Will Haemonetics achieve an EPS of at least $1.27?
This figure is crucial as it sets the baseline for market expectations and can significantly impact stock performance.
Q2
What insights can management provide regarding revenue growth and market demand?
Understanding revenue trends will help gauge the company's performance and future prospects in the competitive health care supplies market.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential for Haemonetics to outperform due to its recent product innovations and market expansion efforts.
Supporting evidence
The company has a strong history of beating EPS estimates, with a 75% success rate over the last eight quarters.
Recent trends in the health care sector indicate increasing demand for blood management solutions, which could benefit Haemonetics.
Options pricing suggests a significant move, indicating that traders expect more volatility than the consensus reflects.
Key risk
If revenue growth is reported below $331M, it could undermine the bullish sentiment.
Pre-commit to what would confirm each case.
The market is closely watching these metrics to determine Haemonetics' ability to sustain growth and manage costs effectively.
Bull confirmed if
Reporting an EPS above $1.31 and revenue exceeding $342M would confirm a strong growth trajectory.
Bear confirmed if
An EPS below $1.25 or revenue falling short of $331M would indicate potential issues in sales or profitability.
What the market is pricing for the move.
Implied Move
±11.83%
Historical Avg
±11.7%
The options market is pricing in a substantial move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±13.5% while HAE has averaged ±11.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
38.6%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 3 of 30 (10%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 3.3%, with a raw directional average of +2.1% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
112.43%
of float
Insider
1.26%
of float
Holders
465
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
5,909,258 sh · $601.0M
12.99%
5.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Haemonetics beats expectations, history suggests a stock increase of around 5.86%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of approximately 18.71%, reflecting investor disappointment and concerns about future performance.
The lines on the call that would change the story.
Neuberger Berman Group, LLC
4,179,443 sh · $425.1M
9.19%
17.4%
Vanguard Portfolio Management LLC
2,546,394 sh · $259.0M
5.60%
-0.5%
AQR Capital Management, LLC
2,266,489 sh · $230.5M
4.98%
-32.5%
Vanguard Capital Management LLC
2,059,578 sh · $209.5M
4.53%
-1.5%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.